Exact Sciences

EXAS

$
101.06
(
-0.1
%)
(
+
-0.1
%)
+
-36.3
%
64.40
NASDAQ

Last Price

12/05/25, 09:30 AM
 EDT

Margin of Safety

Current Compounder
$
64.40

PORTFOLIO CATEGORY

Modeled fair value

0% to 15%
$12.435 billion

Allocation Suggestion

Modeled fair value

Model Basis

LAST REFINED:
August 7, 2025
The current model INCLUDES the following assets and assumptions:
The current model is based on operating metrics, including:
  • Full-year 2026 revenue of $3.598 billion, representing year-over-year growth of 13.9%.
  • Screening segment revenue of $2.851 billion, representing year-over-year growth of 15.7%.
  • Precision Oncology segment revenue of $746 million, representing year-over-year growth of 7.5%.
  • Operating income of $349 million.
  • Net income of $329 million to $369 million, or earnings per share (EPS) of $1.70 to $1.91.
  • Excludes blood-based screening tools.
The current model EXCLUDES the following assets:

Research Deep Dive

Last Updated:

Overview

Solt DB Invest will introduce Base Research for our coverage ecosystem over the next month to coincide with third-quarter 2023 earnings announcements. Check back soon!

Technology Platform

Pipeline

Portfolio

Opportunities & Advantages

Challenges & Risks

Development Risk 

Regulatory Risk 

Commercial Risk 

Dilution Risk 

Valuation Risk 

Geopolitical Risk 

Unique Risks 

Modeling Insights

News Flow & Timing